Figure 1.
Flow chart showing 909 HIV-infected individuals recruited for final analysis.
T-SPOT.TB = (commercial form of interferon-gamma release assay from Oxford Immunotec, Abingdon, UK); TST = tuberculin skin test; IPT = isoniazid preventive therapy.
Table 1.
Demographic data of enrolled participants at time of simultaneous T-SPOT.TB and TST.
Table 2.
Predictors of positive TST and T-SPOT.TB result in multivariate logistic regression analysis.
Table 3.
Agreement between T-SPOT.TB assay and Tuberculin Skin Tests, stratified by age and CD4+ lymphocyte counts groups and BCG vaccination status.
Figure 2.
Positive rate of TST by different cut-off point, T-SPOT.TB and dual positive rate.
TST = tuberculin skin test.
Table 4.
Demographic data of the five incident active TB cases.
Table 5.
Incidence and relative risks for active TB in HIV-infected individuals with positive TST, T-SPOT.TB and dual positive results, compared with individuals with negative results.
Figure 3.
Risk for active TB among patients with dual positive results of TST and T-SPOT.TB stratified by receiving IPT or not.
The TB incidence was 4.9 case per 100 PY for participants without IPT vs. 0.66 case per 100 PY for participants received IPT, p<0.05 by log-rank test. TST = tuberculin skin test; IPT = isoniazid preventive therapy.